CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/28/23 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
   |
12 |
| 03/09/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
43 |
| 03/29/22 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
80 |
| 06/02/21 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
6 | |
| 03/30/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
56 |
| 03/12/20 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
85 |
| 03/18/19 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
78 |
| 04/02/18 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
70 |
| 03/31/17 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
71 |
| 04/05/16 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
8 |